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Abstract 
 
What is the central question of this study?  
Does chronic reduction of neuronally generated nitric oxide in the hypothalamic 
paraventricular nucleus affect the set-point regulation of blood pressure and 
sympathetic activity destined to the kidneys? 
 
 
What is the main finding and its importance?  
Within the hypothalamic paraventricular nucleus, nitric oxide generated by neuronal 
nitric oxide synthase plays a major constitutive role in suppressing long term the levels 
of both ongoing renal sympathetic activity and arterial pressure in conscious Wistar 
rats. This finding unequivocally demonstrates a mechanism by which the diencephalon 
exerts a tonic influence on sympathetic discharge to the kidney and may provide the 
basis for both blood volume and osmolality homeostasis. 
 
 
The paraventricular nucleus of the hypothalamus (PVN) plays a crucial role in 
cardiovascular and neuroendocrine regulation. Application of nitric oxide donors to the 
PVN stimulates GABAergic transmission, and may suppress sympathetic nerve 
activity (SNA) to lower arterial pressure. However, the role of endogenous nitric oxide 
within PVN in regulating renal SNA chronically remains to be established in conscious 
animals. To address this, we used our previously established lentiviral vectors to 
selectively knock down neuronal nitric oxide synthase (nNOS) in the PVN of conscious 
Wistar rats. Blood pressure (BP) and renal SNA were monitored simultaneously and 
continuously for 21 days (n=14) using radio-telemetry. Renal SNA was normalised to 
maximal evoked discharge and expressed as a percent change from baseline. The 
PVN were microinjected bilaterally with a neurone-specific tetracycline-controllable 
lentiviral vector, expressing a short hairpin miRNA-30 (shRNA) interference system 
targeting nNOS (n=7) or expressing a mis-sense as control (n=7). Recordings 
continued for a further 18 days. The vectors also expressed GFP, and successful 
expression in the PVN, and nNOSknockdown, was confirmed histologically post-hoc. 
Knock-down of nNOS expression in the PVN resulted in a sustained increase in BP 
(95±2 to 104±3 mmHg, P<0.05), with robust concurrent sustained activation of renal 
sympathetic nervous activity (>70%, P<0.05). The study reveals a major role for 
nNOS-derived nitric oxide within the PVN in chronic set-set point regulation of 
cardiovascular autonomic activity in the conscious, normotensive rat. 
  
Introduction 
The paraventricular nucleus (PVN) of the hypothalamus is known to play a key role in 
the central regulation of sympathetic tone in health and disease.(Saper et al., 1976; 
Ciriello & Calaresu, 1980; Swanson & Sawchenko, 1983; Caverson et al., 1984; Coote 
et al., 1998; Ranson et al., 1998; Patel, 2000; Pyner & Coote, 2000; Kenney et al., 
2003) Recently, there has been a particular focus on the regulatory role of nitric oxide 
within the PVN (Li et al., 2002a; Li et al., 2002b; Wang et al., 2005; Pyner, 2009; 
Watkins et al., 2009; Sharma et al., 2011). Neuronal nitric oxide synthase (nNOS) is 
the enzyme largely responsible for the production of nitric oxide in neurons, and is 
expressed in a number of brain regions important in autonomic control, including the 
PVN (Garthwaite & Boulton, 1995). nNOS expression in the PVN has been shown to 
be reduced in sympathoexcitatory diseases including heart failure (Zhang et al., 1998; 
Schultz, 2009; Pyner, 2014) and chronic intermittent hypoxia-induced hypertension 
(Huang et al., 2007). In contrast, nNOS expression is increased in the PVN of 
spontaneously hypertensive (Plochocka-Zulinska & Krukoff, 1997) and renovascular 
hypertensive rats (Krukoff et al., 1995), where it is hypothesised to compensate for the 
sympathetic hyperactivity characteristic of these models.  
 
Functionally, experimental approaches which either increase neuronal excitability or 
decrease nitric oxide transmission in the PVN, tend to increase sympathetic drive and 
arterial blood pressure, at least as observed in the acute setting (Kannan et al., 1989; 
Martin & Haywood, 1992; Li et al., 2001; Hirooka et al., 2011). In conscious rats, the 
short-term blockade of nNOS transmission, by infusing nNOS-specific antisense 
oligonucleotides into the PVN, has been shown to produces increases in blood 
pressure and heart rate for several hours (Wang et al., 2005), with evidence that a 
reduction in nitric oxide transmission in the PVN may contribute to sympathoexcitation 
in heart failure (Zhang et al., 1998). Conversely, acute treatments which either 
increase synaptic inhibition or increase nitric oxide transmission in the PVN, produce 
decreases in sympathetic drive and blood pressure (Zhang & Patel, 1998; Li et al., 
2002b; Akine et al., 2003). These functional data, together with neuroanatomical 
findings (Watkins et al., 2009), suggest that nNOS-derived nitric oxide in the PVN 
plays a key role in the acute regulation of sympathetic outflow and arterial pressure.  
 
 
Taken together, these data suggest an important role for nNOS in the PVN in 
regulation of the sympathetic outflow in both health and disease (Coote, 2005). 
However, direct evidence that endogenous nNOS activity in the PVN plays a role in 
the long-term physiological regulation of cardiovascular sympathetic tone is lacking. 
 
Previous studies examining a role for nitric oxide in the PVN for sympathetic control 
have been largely limited to acute effects, observed over a scale of minutes or hours 
in anesthetized animals (Zhang et al., 1997; Zhang et al., 2001). Longer time scale 
studies have involved nNOS overexpression in the PVN; however, interpretation here 
is confounded as cells that do not normally produce nNOS now express it, which may 
limit relevance to the physiological setting.(Li et al., 2002b) Thus, we set out to identify 
the role of nNOS in the PVN in determining long-term sympathetic outflow and 
cardiovascular control, in conscious, unrestrained healthy rats. In order to chronically 
decrease endogenous levels of nNOS in the PVN, we have used our previously 
published lentiviral vector knock-down system reported to cause a ~55% reduction in 
nNOS protein (Liu et al., 2010; Liu et al., 2011). 
 
 
Methods 
 
Ethical Approval 
All experiments performed were carried out according to the guidelines laid down by 
our institution's animal welfare committee, and conform to the principles and 
regulations described by Grundy (2015). Experiments were in accordance with the 
European Commission Directive 86/609/EEC (European Convention for the Protection 
of Vertebrate Animals used for Experimental and Other Scientific Purposes) and the 
UK Home Office (Scientific Procedures) Act (1986), with project approval from the 
University of Bristol Animal Care and Use Committees. 
 
Experiments were carried out on adult male Wistar rats bred within the University of 
Bristol’s animal facility (n=25, 280-320g), individually housed with standard rat chow 
and water available ad libitum and kept on a 12 hour light-12 hour dark cycle. Surgeries 
were performed aseptically under ketamine (60 mg kg−1; i.m.) and medetomidine (250 
μg kg−1, i.m.) anaesthesia, with sufficient depth of anaesthesia ensured by testing 
intermittently (approximately every 20 min) for the absence of limb withdrawal reflexes. 
Analgesia was administered post-surgically.  
 
Telemetric blood pressure and renal nerve recordings 
Arterial pressure and renal sympathetic nerve activity (renal SNA) were monitored 
continuously in rats using an implanted telemetric device (model TRBSNA; Telemetry 
Research Ltd, Auckland, New Zealand) as per (McBryde et al., 2013). Briefly, rats 
were anaesthetised and the abdominal aorta exposed and cannulated just above the 
iliac bifurcation. The catheter was inserted until the tip rested just below the left renal 
artery branch point, and held in place using a tissue adhesive (VetBond, 3M, USA) 
and cellulose matrix. The transmitter body was placed in the abdominal cavity, and the 
electrode wire leads tunnelled through to an incision on the left flank. The left renal 
artery was exposed via a retroperitoneal approach, the renal nerves gently freed from 
surrounding connective tissue and placed over the bipolar recording electrodes. The 
electrodes themselves were secured in place with sutures to the wall of the renal artery 
and abdominal aorta, and a biocompatible silicone elastomer (Kiwk-Sil, WPI, Eu) used 
to isolate both electrode and nerve. The incisions were closed, and rats recovered for 
at least 7 days post-operatively, with analgesic treatment once daily for 3 days 
(Buprenorphine, 0.01 mg/kg per dose). 
 
Arterial pressure and renal SNA signals were sampled at 500 Hz using an analog-
digital data acquisition card (PCI 6024E National Instruments, Austin, Texas) and 
displayed by a data acquisition program (Universal Acquisition 11, University of 
Auckland, Auckland, New Zealand). Heart rate (HR) was derived from the inter-pulse 
interval of the arterial pressure waveform. The renal SNA signal was amplified, filtered 
between 50-5000 Hz, full-wave rectified and integrated using a low pass filter with a 
20 ms time constant. At least 7 days were allowed for recovery before a 3 day baseline 
period was recorded. Arterial pressure, renal SNA and heart rate were recorded for 24 
hours a day as 2 second averages, with high frequency (500 Hz) periods of 5 minutes 
saved every hour to verify signal quality. Two days before and 7 after lentiviral 
injection, rats were briefly exposed to a bolus of cigarette smoke (5 ml in air), which 
activates the nasopharyngeal nerve endings and provokes a powerful reflex increase 
in renal SNA. The magnitude of this response was used to check that the renal SNA 
signal remained viable and responsive throughout the experiment. The success rate 
for renal SNA recordings for the full experimental protocol (24 days) was 
approximately 65%. 
 
Lentiviral (LVV) knock-down of nNOS in neurones 
For nNOS knock-down, we used our binary LVV system which has been validated 
previously in hippocampus and dorsal vagal complex (Liu et al., 2008; Liu et al., 2010; 
Liu et al., 2011). This system requires co-operative action of two LVVs. The first vector 
– LV-Tretight-eGFP-miR30-shRNA/nNOS harbours an expression cassette for an 
miRNA30 (miR30)-based short hairpin (shRNA) interference system (Stegmeier et al., 
2005) under control of a Tet-sensitive promoter. The system expresses a miRNA30-
like hairpin targeting nNOS fused to the 3’ end of the sequence encoding enhanced 
green fluorescent protein (eGFP); this design facilitates targeting of the RNA duplex 
into the RNA-induced silencing pathway. The second vector – LV-mCMV/SYN-tTA - 
expresses tetracycline-sensitive transactivator Tet-off under control of an enhanced 
synapsin-1 promoter. This neurone-specific nNOS knock-down system works by 
expression of the Tet-off transactivator (tTA) from LV-mCMV/SYN-tTA which contains 
the bidirectional amplified SYN promoter to ensure high level of tTA. tTA binds to 
Tretight promoter in LV-Tretight-GFP-miR30-shRNA/nNOS and activates the 
expression of shRNA/nNOS. For simplicity, this system is hereafter referred to as LVV-
shRNA/nNOS. As a control, we used a similar viral system directed against firefly 
luciferase (Luc); LV-Tretight-GFP-miR30-shRNA/Luc plus  LV-mCMV/SYN-tTA.  This 
construct does not affect nNOS protein in vivo: (Liu et al., 2010; Liu et al., 2011) and 
will be further referred to as LVV-control for simplicity.  
 
LVV protocol and microinjections 
On day 0, rats were anaesthetised as above, placed in a stereotaxic frame using non-
traumatic ear bars, and underwent bilateral microinjections of viral vectors (LVV-
shRNA/nNOS and LV-control) into the PVN using glass micropipettes with tip 
diameters of ∼25 μm. Microinjections were made 1.8 mm caudal to bregma, ±0.3 mm 
lateral to the midline and 7.5 mm below the dorsal surface of the cerebrum. Titres of 
both LVV used were 2–6 × 109TU ml−1, with an injected volume of 0.5 μL per site. 
MAP, HR and RSNA were recorded for a further 21 days. In two rats injected with 
LVV-nNOS the recording window was extended to 55 days to investigate the 
persistence of the observed pressor responses.  
 Because of the known brain region differences in the efficacy of the viral system used 
(Liu et al., 2010) and to validate the efficacy of nNOS knock-down in the PVN 
specifically, LVV-nNOS was microinjected unilaterally in a sub-group of rats (n=3), and 
nNOS expression both compared and quantified immunocytochemically (see below) 
in the injected vs non-injected sides. For this, Fiji binary representation particle 
analysis of eGFP and nNOS was used to determine the % of each protein in both the 
left and right PVN regions. 
 
Immunocytochemistry 
Rats were terminally and deeply anaesthetised (induction with halothane, 5% in 
oxygen followed by sodium pentobarbital 40 mg/kg i.p.). The depth was confirmed by 
failure of the animal to respond to a noxious pinch of a limb or the tail and evidence of 
suppression of respiratory depth and frequency. Subsequently, rats were perfused 
transcardially with fixative (5% formaldehyde in 0.1 M phosphate buffer, pH 7.4, at 
4°C) and their brains removed and post fixed for 2 h in the same solution. They were 
cryoprotected overnight using 30% sucrose in phosphate buffer at 4°C. The brains 
were trimmed above the dorsal 3rd ventricle and lateral to the reticular thalamic 
nucleus. Coronal sections 40 µm were cut on a freezing microtome with every section 
collected into a series of 3 wells. The freely floating sections were stained using 
standard immunofluorescence double labelling techniques (blocking using  10% goat 
serum and permeabilisation using 0.1% Triton X) and employed primary antibodies 
against eGFP (A11122,  Life Technologies Ltd, UK) in a concentration of 1:2000, and 
NeuN Chemicon International, USA) in a concentration of 1/200. Sections from 
animals with unilateral LVV-nNOS microinjections were incubated with primary 
antibodies against eGFP (as above) and NOS1 (sc-5302, Santa Cruz Biotechnology 
Inc, GE) in concentrations of (1:25, 1:50 and 1:100). The eGFP antibody was 
visualised with secondary antibody Goat-anti-Rabbit-AF488 (A11008, Life 
Technologies Ltd, UK) used 1:500 and the NeuN or NOS1 antibody with 1:500 
biotinylated anti-mouse IgG (BA9200, Vector Laboratories Ltd, UK) tagged with 1:500 
Streptavidin-AF594 (S11227, Molecular Probes, UK). All incubations were performed 
for 1h at room temperature except the primary antibody incubation which lasted 24h 
at 4°C. Upon staining the sections were mounted on Super frost slides, airdried at 
room temperature and cover slipped using vectashield (H-1000, Vector Laboratories 
Ltd, UK). Slides were inspected on a Leica fluorescent microscope under 5-20x 
magnification, and images captured with AxioVision software. Omission of the primary 
antibody resulted in no detectable staining.  
 
Data analysis 
From the arterial pressure waveform, values for systolic, diastolic, mean and pulse 
pressure, and heart rate were calculated. Spontaneous ramps in arterial pressure and 
heart rate were used to derive spontaneous cardiac baroreceptor reflex gain, and low 
and high frequency spectral components of the blood pressure and heart rate signals 
assessed to give indirect insight in to changes in global autonomic tone as described 
previously (Waki et al., 2006). Renal SNA is expressed as a percentage, where 100% 
was set as the average integrated value across the baseline period as previously 
described by us (McBryde et al. 2013). Values are presented as daily average mean 
± standard deviation (SD). Data were compared between baseline and nNOS time 
points, by repeated measures 2-way ANOVA with time and experimental group as 
factors (SigmaPlot v.12.0, Systat Software Inc, 2011). Where appropriate, post-hoc 
comparisons were made using the Holm-Sidek multiple comparison test. Differences 
within or between groups with p values <0.05 were considered significant. 
 
 
Results 
Cardiovascular response to nNOS knock-down.  
Baseline (Days -3 to 0) mean arterial pressure (MAP) was similar between LVV-
shRNA/nNOS and LVV-control rats (95±5 mmHg vs. 97±6 mmHg, N.S.). As can be 
seen in Fig 1, following microinjection of LVV-shRNA/nNOS on Day 0 MAP increased 
slowly from ~Day 7 reaching a stable plateau around Day 10 (104±7 mmHg; p=0.041). 
LVV-control animals showed no change in MAP across the entire experimental period. 
Figure 2 (panel A) shows the individual data from a rat where the BP recording was 
continued out to 55 days; in this rat the blood pressure remained above baseline levels 
as was found in a second rat that was followed out to this extended time point. Heart 
rate was not significantly different between LVV-shRNA/nNOS and LVV-control 
groups at pre- (311±27 vs. 330±45 bpm, respectively) and did not change significantly 
in either group post- viral microinjection. The increased BP persisted in the two LVV-
shRNA/nNOS rats that were maintained for 55 days, which is consistent with the 
known long-acting expression of transgenes by Lentiviruses (Naldini et al., 1996). 
 
Renal sympathetic response to nNOS knock-down.  
Figure 1 shows the temporal association between the rise in MAP and the concurrent 
rise in renal SNA in LVV-shRNA/nNOS rats. Renal SNA in LVV-shRNA/nNOS rats 
increased to over 70% above baseline (+75±44%, p=0.034), while there was no 
significant change in LVV-control rats (-7±37%, NS; Figs 2 & 3). Figures 2B and 2C 
show traces of raw renal SNA, cardiac association of the renal SNA signal, and the 
renal SNA responses to activation with nasopharyngeal stimuli before (Day -1) and 
after (Day 15) nNOS knock-down; comparable responses were evoked confirming the 
validity of the recording with time.  
 
Baroreceptor reflex and heart rate variability.  
No change in the spontaneous cardiac baroreceptor reflex gain (sBRG) was seen with 
nNOS knock-down at baseline (LVV-control: -6.7±0.3 versus LVV-shRNA/nNOS -
6.6±0.5 mmHg.bpm-1, NS) or at week 3 (LVV-control: -6.3±0.3 versus LVV-
shRNA/nNOS: -6.3±0.5 mmHg.bpm-1, NS, Fig 3). Heart rate variability, as measured 
by the ratio of low frequency and high frequency power (LF:HF) of pulse interval, 
showed a significant increase from baseline to week 3 in LVV-shRNA/nNOS rats 
(0.13±0.08 to 0.22±0.07, p=0.032) but not in the LVV-control group (0.11±0.05 to 
0.10±0.03, NS, Fig 3). This increase in LF:HF ratio gives indirect evidence for a shift 
towards sympathetic dominance in cardiac sympatho-vagal balance. The LF 
component of SBP increased significantly in LVV-shRNA/nNOS rats from baseline to 
week 3 (3.20±0.33 to 3.66±0.34 mmHg2, p=0.016) but not in LVV-control rats 
(3.12±0.32 to 3.21±0.34 mmHg2, NS), indicating a general increase in vasomotor 
sympathetic drive, and consistent with the increase in renal SNA. Taken together, 
these observations suggest that the increased sympathetic outflow in LVV-
shRNA/nNOS rats is global.   
 
Immunohistochemical confirmation of vector expression.  
Figure 4 shows immunohistochemical validation of nNOS knock-down, with LVV-
shRNA/nNOS expression associated with a ~50% reduction in nNOS expression 
compared to the contralateral PVN that was devoid of viruses mediating nNOS 
knockdown; this was consistent in all rats studied. 
 
Discussion 
The data reported herein demonstrate for the first time that LVV-mediated long term 
knock down of nNOS activity targeted to the PVN produces sustained increases in 
both renal sympathetic drive and arterial pressure in healthy conscious rats. Our 
observation of a 70% increase in renal SNA and a shift towards sympathetic 
predominance in the autonomic balance in LVV-shRNA/nNOS transfected rats 
suggests that the hypertension in these animals is driven at least partially by 
sympathetic actions on the kidney and heart. These results have important 
implications for interpreting findings by others that nitric oxide levels in the PVN are 
depressed in cardiovascular disease, and supports the hypothesis that chronically 
reduced (endogenous) nitric oxide signalling in the PVN can cause sustained 
sympathetic hyperactivity (Huang et al., 2007; Schultz, 2009). 
 
Consideration of the methodology employed 
The present study used lentiviral shRNA to knock-down endogenous nNOS in the PVN 
that revealed a long term role for this protein in regulating the circulation. We have 
previously shown, using western blot analysis, that this binary system reduces nNOS 
protein expression in cell lines in vitro by up to 82% and in vivo in dorsomedial 
medullary neurons by ~55%, while the control construct caused no measurable effects 
(Montero et al., 2010; Liu et al., 2011). The latter is consistent with the nNOS 
knockdown we found in the PVN herein. 
 
In the in vivo animal, it is unknown how long expression takes to reach a functionally 
effective reduction in nNOS protein. The use of a viral vector approach, as opposed 
to a knockout mouse, gives the benefit of allowing a highly restricted circumscribed 
brain region to be targeted. In comparison to over-expression of nNOS, the use of 
knock down is advantageous because only neurones that endogenously express 
nNOS will be affected; in contrast to the situation when a newly expressed exogenous 
protein may appear in uncontrolled concentrations as well as in cells which normally 
do not produce it (Li et al., 2001; Zheng et al., 2011). Moreover, the use of LVV permits 
relatively long term (up to several months) of stable expression (Coleman et al., 2003). 
In addition, LVV are essentially non-immunogenic in the CNS. This may be important 
because pro-inflamatory properties of previously used adenoviral vectors (Liu & 
Muruve, 2003) could lead to up-regulation of nNOS, complicating interpretation of 
data. While a viral vector strategy to knock down nNOS limits compensation, we 
cannot rule out compensatory changes, perhaps in the form of up regulation of eNOS 
and/or iNOS, which can also occur after surgical trauma (Petrov & Rafols, 2001). 
However, any such changes would be expected to oppose a reduction in nitric oxide, 
and thus reduce the observed pressor and sympathoexcitatory responses. If this has 
occurred, then the magnitude of the rise in arterial pressure and renal SNA will have 
been underestimated.  
 
It might be expected that multiple intrinsic physiological systems would oppose any 
increase in arterial pressure such as that we have observed. The fact that nNOS 
knock-down in the PVN of a normal adult Wistar rat is able to produce such a dramatic 
and sustained increase in renal SNA, with a moderate increase in arterial pressure, 
supports the notion of the PVN as a ‘central command’ centre for the sympathetic 
outflow (Dampney et al., 2005). Although we did not detect any changes in the 
spontaneous cardiac baroreceptor reflex gain, we speculate that the baroreflex control 
of sympathetic outflow to the arterioles, including those in the kidney, is re-set to permit 
adjustment of the set-point of vasomotor tone, and hence arterial pressure. Our data 
is compatible with the notion that the PVN is a powerful and important regulator of the 
long-term level of sympathetic outflow in health. 
 
nNOS activity in the PVN: a major regulator of physiological levels of 
autonomic activity 
Mechanistically, it has been shown that nitric oxide inhibits the firing of PVN neurons 
projecting to autonomic centres in the medulla oblongata, such as the rostral 
ventrolateral medulla, and spinal cord (Li et al., 2002a; Li et al., 2003). Sutton et al 
have published findings showing that as well as directly projecting to the NTS, nNOS-
positive PVN neurons also directly innervate pre-ganglionic sympathetic output 
neurons in the thoracic spinal cord (Sutton et al., 2014). This suggests that nNOS-
dependent alterations in PVN outflow may influence sympathetic tone via this direct 
pathway. Alternatively, substantial neuroanatomical and functional evidence supports 
nNOS-released nitric oxide driving an inhibitory (GABAA-ergic) system regulating PVN 
output activity affecting sympathetic tone and arterial pressure (Li et al., 2003; 
Dampney et al., 2005; Pyner, 2009; Patel & Zheng, 2012). In rats with heart failure, 
the inhibitory effects of nitric oxide in the PVN on sympathetic nerve discharge appear 
to be impaired (Sharma et al., 2011) and this is associated with both a down-regulation 
of nNOS via an AT1 receptor mediated mechanism (Sharma et al., 2013) and a loss 
of GABAergic inhibition (Zhang et al., 2002). In contrast, ectopic nNOS expression in 
the PVN of heart failure rats has been shown to reduce the glutamatergic drive in this 
region (Zhang et al., 2001; Zheng et al., 2011).   
 
It has been suggested that nitric oxide acts via excitation of GABAergic interneurones 
impinging onto PVN sympathetic pre-motor neurons (Biancardi et al., 2011) thereby 
acting as a ‘brake’ on sympathetic outflow (Zhang et al., 1997; Hirooka et al., 2011). 
This is supported by immunohistochemical investigations showing that although 
spinally-projecting PVN neurons rarely contain either GABA or nNOS, they are 
surrounded by dense populations of interneurons which show positive staining for 
GABA or nNOS, with co-localization being rare (Watkins et al., 2009). A somewhat 
similar situation exists in the NTS where nitric oxide was shown to potentiate GABA 
release via cADP-rybose pathway and sensitisation of ryanodine-sensitive stores 
(Wang et al., 2006b). We have previously shown that nitric oxide potentiates GABA 
release via cGMP-mediated sensitisation of intracellular Ca2+ stores (Wang et al., 
2006a; Wang et al., 2006b) while confirming that nitric oxide within the PVN is 
important for determining the long-term level of sympathetic outflow, our results do not 
determine whether this occurs via direct projections, or changes in local GABAergic 
inhibition. 
 
In contrast to the present study, Ramchandra et al. (2013) injected muscimol or 
glycine into the PVN of conscious sheep and reported no change in blood pressure 
or renal sympathetic nerve activity, suggesting that there was no tonic 
sympathoexcitatory drive from the PVN regulating arterial pressure. Species 
differences aside, this pan-neuronal approach could be explained by simultaneous 
inactivation of opposing excitatory and inhibitory drives regulating sympathetic 
activity with a nulling out of a response on blood pressure. In contrast, our lentiviral 
approach used an amplified synapsin promoter that will only affect neurones (not 
astrocytes) and, importantly, only affects those neurones in which nNOS is active 
constituitively. Our findings support the presence of constituitively active nNOS 
affecting preferentially an inhibitory system. The presence of GABA- and nNOS- 
containing interneurons in the PVN (Watkins et al., 2009) and their close apposition 
provides the neuro-anatomical substrate for discrete cross-talk allowing selective 
activation of an inhibitory synapse on to excitatory PVN sympathoexcitatory 
neurones. 
 
Our results did not show a change in cardiac baroreflex gain or heart rate variability, 
as has been previously observed with global, chronic changes to PVN neuronal activity 
(Geraldes et al., 2014). This suggests that nitric oxide regulation of PVN activity may 
not be critical for cardiac parasympathetic activity and baroreceptor reflex control of 
heart rate. However, our data do support that nNOS activity in the PVN is an important 
factor regulating sympathetic activity to the heart, as indicated by alterations in the 
HF:LF ratio of the heart rate spectra, as well as vasomotor sympathetic control. We 
acknowledge that this will need further confirmation, but our data lead us to propose 
that nitric oxide in the PVN predominantly modulates sympathetic rather than 
parasympathetic outflows. 
 
The Regulation of nNOS Activity in Health and Disease: 
The factors which drive the normal expression and activity of nNOS have not been 
fully elucidated. Afferent connections from the nucleus tractus solitarii have been 
shown to impinge on GABAergic and nitric oxide-producing interneurons in the PVN 
(Affleck et al., 2012), which supports a role for homeostatic reflex activity (e.g. 
baroreceptor, peripheral chemoreceptor, Bainbridge reflexes) in the control of 
sympathetic outflow via PVN-nNOS pathways. At a cellular level, nNOS expression 
has been shown to be regulated by the inducible transcription factor c-jun,(Cheng et 
al., 2012; Cheng et al., 2014) implying that nNOS expression may be responsive to 
stimuli such as stress, infection and inflammation.  
 
In disease states, nitric oxide levels are typically depleted by oxidative stress or NOS 
uncoupling (Moens et al., 2008; Antoniades et al., 2009; Crabtree & Channon, 2011) 
both of which are known to occur in the brain under conditions of hypertension 
(Zimmerman et al., 2004; Oliveira-Sales et al., 2010; Hirooka et al., 2011; Francis & 
Davisson, 2014) and heart failure (Zucker, 2006; Patel & Schultz, 2013). Together with 
the present data, these studies implicate insufficient nNOS signalling in the PVN as a 
potential causal mediator of sympathetic excess, which could underpin a plethora of 
disease states.  
 
In conclusion, our data fully support the notion that nNOS-generated nitric oxide in the 
PVN of Wistar rats is acting as a physiological ‘brake’ on sympathetic outflow. 
Moreover, the tonicity of the inhibitory system in the PVN provides neural plasticity 
permitting the set-point control of arterial pressure to be adjusted. A future challenge 
will be to see under what physiological conditions this plasticity is harnessed to 
maintain homeostasis.  
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Figure 1 
Chronic reductions in Nitric Oxide in the PVN produce sustained 
sympathoexcitation and hypertension. Group daily averages of mean arterial 
pressure (MAP) heart rate (HR) and renal SNA responses to nNOS knock-down in the 
PVN (Microinjection of LVV-shRNA/nNOS on Day 0 indicated by dashed line). 
Mean±sem, * p<0.05 from Baseline (repeated measures ANOVA, Factors: Time and 
Group). Note the similar temporal profile of the increase in renal SNA and MAP. 
Figure 2 
A: Typical individual response to nNOS knock-down (Microinjection of LVV-
shRNA/nNOS indicated by a dashed line). 2 hour averages of mean arterial pressure 
(MAP), heart rate (HR) and renal SNA shown, and the MAP and HR responses on 
days 50-55. B: Representative high-frequency recordings before and after nNOS 
knock-down. Arterial pressure (AP), renal SNA integrated (RSNAi) and original 
(RSNAo) during taken while the rat was quiescent at baseline (Day -2) and peak 
response (Day 20). C: Confirmation of renal SNA recording viability over time. 
This figure shows the cardiac association (integrated renal SNA signal overlaid and 
averaged over successive systolic beats), and the response to nasopharyngeal 
activation with a brief exposure to cigarette smoke (insets, smoke exposure indicated 
by grey arrow) of the renal SNA recordings 1 days before and 15 days after LVV-
nNOS microinjection. 
 
Figure 3 
Group data showing cardiovascular and sympathetic responses to nNOS knock-
down in the PVN. Mean arterial pressure (MAP), renal SNA, low frequency to high 
frequency ratio of R-R interval (LF:HF) and spontaneous baroreflex gain (sBRG) 
during baseline (Days -3 to -1) and nNOS knock-down (Day 15-18).  # indicates 
p<0.05, nNOS vs. Control. Note: the LF:HF ratio is increased in nNOS vs. control rats 
indicating that cardiac sympatho-vagal tone may be decreased. 
 
Figure 4  
Demonstrating efficacy of nNOS knockdown in the PVN using lentiviral 
mediated shRNA. Top and middle: Immuno-histologically stained nNOS (red) in a 
brain section at Bregma -2.0mm showing how an ipsilateral injection (left side) of 
nNOS knockdown virus (green; LV-Tretight-eGFP-miR30-shRNA/nNOS) into the PVN 
reduced nNOS expression. Note that the occurrence of eGFP corresponds with a 
diminution of nNOS immunofluorescence (compare regions c with d), whereas the 
more lateral regions of the PVN (e.g. a & f) are relatively unaffected. Bottom: 
Quantitative assessment of nNOS knockdown. This was computed using Fiji binary 
representations particle analysis of eGFP and nNOS to determine the % of each 
region (a-f) of eGFP versus nNOS. A schematic representation of the 3rd ventricle is 
overlaid in blue. 
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